Introduction {#H1-1-ZOI190240}
============

Mineralocorticoid receptor antagonists (MRAs), such as spironolactone and eplerenone, have been associated with reductions in mortality in patients with stable chronic heart failure with reduced ejection fraction (HFrEF).^[@zoi190240r1],[@zoi190240r2]^ In patients with stable heart failure with preserved ejection fraction (HFpEF), a randomized clinical trial (RCT) has suggested that MRA is associated with reductions in heart failure hospitalization, although the study did not meet the primary composite end point of death from cardiovascular causes, aborted cardiac arrest, or heart failure hospitalization.^[@zoi190240r3],[@zoi190240r4]^

In contrast, scarce data are available on the long-term outcomes of MRA use after discharge of patients hospitalized for acute decompensated heart failure (ADHF).^[@zoi190240r5]^ Because these patients had experienced the acute exaggeration of heart failure and hospital admission, they had a high risk for cardiac mortality and rehospitalization owing to worsening of heart failure.^[@zoi190240r6]^ In addition, the contemporary patient population hospitalized for ADHF might be substantially different from stable patients with heart failure who are enrolled in RCTs. The role of MRA in postdischarge management needs to be investigated in patients with ADHF and multiple comorbidities. Therefore, we sought to explore the association between MRA administered at discharge from ADHF hospitalization and clinical outcomes using the registry of a large contemporary all-comer study (Kyoto Congestive Heart Failure \[KCHF\]) in Japan of patients with ADHF hospitalization.

Methods {#H1-2-ZOI190240}
=======

Study Design, Setting, and Population {#H2-1-ZOI190240}
-------------------------------------

The KCHF is a physician-initiated, prospective, multicenter cohort study that enrolled consecutive patients who were hospitalized for ADHF for the first time between October 1, 2014, and March 31, 2016. These patients were admitted into 19 secondary and tertiary hospitals, including rural and urban as well as large and small institutions, throughout Japan. The study protocol was approved by the institutional review board of each participating hospital. A waiver of written informed consent from each patient was granted by the institutional review boards of Kyoto University and each participating center because the study met the conditions of the Japanese ethical guidelines for epidemiological study and the US policy for protecting human research participants.^[@zoi190240r7],[@zoi190240r8]^ This study followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline.

The details of the KCHF study design and patient enrollment are described elsewhere.^[@zoi190240r9],[@zoi190240r10]^ Briefly, we enrolled all patients with ADHF, as defined by the modified Framingham criteria, who were admitted to the participating hospitals and patients who underwent heart failure--specific treatment involving intravenous drugs within 24 hours after hospital presentation. Patient records were anonymized before analysis. Data analysis was conducted from April 2018 to August 2018.

Among the 4056 enrolled patients in the KCHF registry, 3785 patients (93.3%) were discharged alive after hospitalization for ADHF. Clinical follow-up data were collected in October 2017. The attending physicians or research assistants at each participating facility collected clinical events data after the index hospitalization from hospital medical records or from patients, their relatives, or their referring physicians (with patient consent).

In the present study, we compared the clinical outcomes between patients who received MRA at discharge and those who did not receive it. We excluded 11 patients for missing data on left ventricular ejection fraction (LVEF) during the index hospitalization to stratify the analysis according to LVEF. After further exclusions of 57 patients without any follow-up data after discharge, the study population consisted of 3717 patients with known LVEF and postdischarge clinical follow-up data ([Figure 1](#zoi190240f1){ref-type="fig"}).

![Study Flowchart\
KCHF indicates Kyoto Congestive Heart Failure; LVEF, left ventricular ejection fraction; and MRA, mineralocorticoid receptor antagonist.](jamanetwopen-2-e195892-g001){#zoi190240f1}

Definitions {#H2-2-ZOI190240}
-----------

We defined the use of MRA (MRA use group) as any new or continued prescription of spironolactone or eplerenone at discharge from the index hospitalization. The detailed definitions of baseline clinical characteristics have been described previously.^[@zoi190240r10]^

The primary outcome measure was a composite of all-cause death or heart failure hospitalization after discharge from the index hospitalization. Other outcome measures included heart failure hospitalization, all-cause death, cardiovascular death, sudden death, and any-cause hospitalization. Death was regarded as cardiovascular in origin unless obvious noncardiovascular causes could be identified. Cardiovascular death included death related to heart failure, sudden death, death related to stroke, and death from other cardiovascular causes. Sudden death was the unexplained death in a previously stable patient. Stroke was either ischemic or hemorrhagic that required either acute or prolonged hospitalization and had symptoms that lasted more than 24 hours. Heart failure hospitalization was due to worsening of heart failure, requiring intravenous drug therapy.^[@zoi190240r9]^ Heart failure was classified according to baseline LVEF as with reduced LVEF (\<40%) or with preserved LVEF (≥40%).

Laboratory tests were performed on patient admission. Missing laboratory values are presented in eTable 1 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}.

Statistical Analysis {#H2-3-ZOI190240}
--------------------

Categorical variables were presented as numbers with percentages and were compared with the χ^2^ test. Continuous variables were expressed as means with SDs or medians with interquartile range and were compared with an unpaired, 2-tailed *t* test when normally distributed or with Wilcoxon rank sum test when not normally distributed. Cumulative incidences were estimated by the Kaplan-Meier method and compared using the log-rank test. To account for the competing risk of all-cause death, we also calculated cumulative incidence functions of heart failure hospitalization and compared the differences between the 2 groups by Gray test in the matched cohort.^[@zoi190240r11],[@zoi190240r12]^

We regarded the date of discharge as time 0 for clinical follow-up. We compared baseline characteristics with clinical outcomes on the basis of the presence or absence of the use of MRA at discharge from the index hospitalization. To balance the baseline characteristics associated with the selection of MRA use, we used a propensity score--matched cohort design as the main analysis. We also performed analysis in the entire cohort as the sensitivity analysis to explore the robustness of the findings. We compared groups by intention-to-treat analysis, regardless of the discontinuation of MRA during follow-up.

A logistic regression model was developed to make the propensity score for the choice of MRA with 16 baseline variables that were clinically relevant to the choice of MRA treatment ([Table 1](#zoi190240t1){ref-type="table"}). Based on the estimated propensity score, patients in the group who did not receive MRA treatment (no MRA use) were matched with those in the group who received MRA treatment (MRA use) by using a 1:1 greedy matching technique.^[@zoi190240r13]^ We compared the baseline characteristics and evaluated the cumulative incidences using the propensity score--matched cohort. We estimated the hazard ratios (HRs) and 95% CIs with Cox proportional hazards regression model. We conducted subgroup analyses stratified by LVEF (\<40% or ≥40%) and other clinically relevant factors in the Cox models. We assessed the interactions between the subgroup factors and the associations of MRA use in the Cox models. For the sensitivity analysis using the entire cohort, MRA and the 25 clinically relevant risk-adjusting variables were simultaneously included in the Cox models ([Table 1](#zoi190240t1){ref-type="table"}). The continuous variables were dichotomized by clinically meaningful reference values or median values. We expressed the association of the MRA use group with the no MRA use group with all of the outcome measures as HRs with 95% CIs.

###### Patient Characteristics of the Study Population in the Matched and Entire Cohort

  Variable                                                                                                                No. (%)                                                                                  
  ----------------------------------------------------------------------------------------------------------------------- ------------------ ------------------ -------- -------------------- -------------------- --------
  **Clinical Characteristic**                                                                                                                                                                                      
  Age, median (IQR), y                                                                                                    80 (72-86)         80 (73-87)         .37      79 (70-85)           81 (73-87)           \<.001
  Age ≥80 y[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                        536 (52)           534 (52)           .93      793 (47)             1135 (56)            \<.001
  Female sex[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                       469 (45)           468 (45)           .96      763 (45)             905 (44)             .51
  BMI, mean (SD)                                                                                                          23.0 (4.7)         22.8 (4.3)         .26      23.0 (4.8)           22.8 (4.2)           .20
  BMI ≤22[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                       449 (46)           458 (46)           .92      744 (47)             893 (46)             .57
  Origin                                                                                                                                                                                                           
  Ischemic heart disease                                                                                                  335 (32)           323 (31)           .57      530 (32)             675 (33)             .31
  ACS[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                           61 (5.9)           58 (5.6)           .78      86 (5.1)             119 (5.8)            .34
  Hypertensive heart disease                                                                                              260 (25)           269 (26)           .65      368 (22)             559 (27)             \<.001
  Cardiomyopathy                                                                                                          159 (15)           144 (14)           .35      318 (19)             238 (12)             \<.001
  Valvular heart disease                                                                                                  200 (19)           210 (20)           .58      338 (20)             397 (19)             .61
  Other heart disease                                                                                                     80 (7.7)           88 (8.5)           .52      124 (7.4)            170 (8.3)            .29
  Medical history                                                                                                                                                                                                  
  Previous HF hospitalization[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}      314 (30)           299 (29)           .47      549 (33)             768 (39)             \<.001
  Atrial fibrillation or flutter[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                418 (40)           447 (43)           .20      714 (43)             836 (41)             .34
  Hypertension[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                     758 (73)           761 (74)           .88      1135 (68)            1555 (76)            \<.001
  Diabetes[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                         378 (37)           348 (34)           .17      595 (35)             797 (39)             .02
  Dyslipidemia                                                                                                            380 (37)           413 (40)           .14      612 (36)             840 (41)             .003
  Previous myocardial infarction[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}   225 (22)           223 (22)           .92      366 (22)             470 (23)             .37
  Previous stroke[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                               161 (16)           139 (13)           .17      248 (15)             342 (17)             .10
  Previous PCI or CABG                                                                                                    248 (24)           250 (24)           .92      392 (23)             561 (28)             .004
  Current smoking[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                               131 (13)           129 (13)           .89      222 (13)             230 (12)             .08
  VT or VF                                                                                                                44 (4.3)           41 (4.0)           .74      86 (5.1)             68 (3.3)             .007
  Chronic kidney disease                                                                                                  397 (38)           418 (40)           .35      604 (36)             1033 (51)            \<.001
  Chronic lung disease[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                          122 (12)           138 (13)           .29      203 (12)             285 (14)             .09
  Malignant neoplasm                                                                                                      153 (15)           143 (14)           .56      234 (14)             301 (15)             .47
  Dementia                                                                                                                187 (18)           177 (17)           .56      281 (17)             373 (18)             .21
  Social background                                                                                                                                                                                                
  Poor medical adherence                                                                                                  183 (18)           162 (16)           .22      293 (17)             335 (16)             .40
  With occupation                                                                                                         146 (14)           128 (12)           .24      261 (16)             233 (11)             \<.001
  Daily life activities                                                                                                                                                                                            
  Ambulatory[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                    833 (81)           818 (80)           .57      1352 (81)            1589 (79)            .04
  Use of wheelchair, outdoor only                                                                                         66 (6.4)           82 (8.0)           .16      109 (6.6)            165 (8.2)            .06
  Use of wheelchair, outdoor and indoor                                                                                   92 (8.9)           91 (8.9)           .97      141 (8.5)            195 (9.7)            .22
  Bedridden                                                                                                               39 (3.8)           33 (3.2)           .49      59 (3.6)             70 (3.4)             .89
  **Vital Signs at Presentation**                                                                                                                                                                                  
  BP, mm Hg                                                                                                                                                                                                        
  Systolic, mean (SD)                                                                                                     149 (34)           149 (34)           .91      145 (34)             151 (36)             \<.001
  \<90[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                             19 (1.8)           25 (2.4)           .36      48 (2.9)             47 (2.3)             .29
  Diastolic, mean (SD)                                                                                                    87 (24)            85 (24)            .25      85 (24)              85 (24)              .53
  Heart rate, mean (SD), bpm                                                                                              98 (27)            97 (29)            .93      97 (27)              95 (28)              .005
  \<60 bpm[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                      51 (4.9)           72 (6.9)           .051     87 (5.2)             163 (8.1)            \<.001
  Rhythms at presentation                                                                                                                                                                                          
  Sinus rhythm                                                                                                            582 (56)           583 (56)           .96      897 (53)             1173 (58)            .01
  Atrial fibrillation or flutter                                                                                          376 (36)           386 (37)           .65      652 (39)             703 (34)             .006
  NYHA class III or IV[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}             904 (87)           913 (88)           .54      1456 (87)            1766 (87)            .64
  Tests at admission                                                                                                                                                                                               
  LVEF, mean (SD), %                                                                                                      46 (16)            47 (16)            .11      44 (16)              48 (16)              \<.001
  HFrEF (EF \<40%)[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                 368 (36)           370 (36)           .93      722 (43)             661 (32)             \<.001
  BNP, median (IQR), pg/mL                                                                                                699 (381-1228)     699 (402-1218)     .71      700 (381-1216)       721 (403-1287)       .20
  NT-proBNP, median (IQR), pg/mL                                                                                          4640 (2189-9690)   5530 (2947-9692)   .14      4810 (2427-10 773)   6405 (3008-14 109)   .003
  Serum creatinine, median (IQR), mg/dL                                                                                   1.0 (0.7-1.3)      1.1 (0.8-1.4)      \<.001   1.0 (0.8-1.3)        1.3 (0.9-1.9)        \<.001
  eGFR, mean (SD), mL/min/1.73m^2^                                                                                        50 (35-67)         45 (33-59)         \<.001   51 (37-67)           38 (24-55)           \<.001
  \<30 mL/min/1.73m^2^[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}             189 (18)           186 (18)           .86      253 (15)             725 (36)             \<.001
  Blood urea nitrogen, median (IQR), mg/dL                                                                                22 (16-30)         23 (18-32)         .001     21 (16-29)           26 (19-39)           \<.001
  Albumin, mean (SD), g/dL                                                                                                3.5 (0.5)          3.5 (0.5)          .74      3.5 (0.5)            3.5 (0.5)            .04
  \<3.0 g/dL[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                    130 (13)           122 (12)           .54      210 (13)             270 (14)             .52
  Sodium, mean (SD), mEq/L                                                                                                139 (4.3)          139 (4.1)          .34      139 (4.3)            139 (4.1)            .16
  \<135 mEq/L[^b^](#zoi190240t1n2){ref-type="table-fn"}                                                                   131 (13)           101 (9.8)          .04      222 (13)             211 (10)             .007
  Potassium, mean (SD), mEq/L                                                                                             4.1 (0.6)          4.2 (0.6)          .003     4.1 (0.6)            4.3 (0.7)            \<.001
  ≥5.0 mEq/L[^a^](#zoi190240t1n1){ref-type="table-fn"}                                                                    96 (9.3)           108 (10)           .38      135 (8.1)            297 (15)             \<.001
  Hemoglobin, mean (SD), g/dL                                                                                             11.8 (2.3)         11.6 (2.3)         .18      11.9 (2.4)           11.2 (2.3)           \<.001
  Anemia, No. (%)[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                  665 (64)           670 (65)           .82      995 (59)             1462 (72)            \<.001
  MRA before the index admission[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}   117 (11)           112 (11)           .73      522 (31)             129 (6.3)            \<.001
  Medications at discharge                                                                                                                                                                                         
  ACEI/ARB and β-blocker                                                                                                  464 (45)           463 (45)           .96      819 (49)             742 (36)             \<.001
  ACEI or ARB[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                      625 (60)           627 (61)           .93      1051 (63)            1086 (53)            \<.001
  β-Blocker[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                        702 (68)           703 (68)           .96      1203 (72)            1266 (62)            \<.001
  Loop diuretics[^a^](#zoi190240t1n1){ref-type="table-fn"}^,^[^b^](#zoi190240t1n2){ref-type="table-fn"}                   911 (88)           908 (88)           .84      1541 (92)            1474 (72)            \<.001
  Thiazide                                                                                                                40 (3.9)           63 (6.1)           .02      73 (4.4)             145 (7.1)            \<.001
  Tolvaptan                                                                                                               97 (9.4)           92 (8.9)           .70      176 (10)             214 (11)             .99
  Digoxin                                                                                                                 59 (5.7)           58 (5.6)           .92      127 (7.6)            84 (4.1)             \<.001
  Warfarin sodium                                                                                                         236 (23)           242 (23)           .75      420 (25)             504 (25)             .83
  DOAC                                                                                                                    230 (22)           244 (24)           .46      379 (23)             381 (19)             .003

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin-receptor blocker; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BNP, brain-type natriuretic peptide; BP, blood pressure; CABG, coronary artery bypass graft; DOAC, direct oral anticoagulant; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal-proBNP; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; VF, ventricular fibrillation; VT, ventricular tachycardia.

SI conversion factors: To convert albumin to grams per liter, multiply by 10; blood urea nitrogen level to millimoles per liter, multiply by 0.357; BNP to nanograms per liter, multiply by 1.0; eGFR to milliliters per second per meters squared, multiply by 0.0167; hemoglobin level to grams per liter, multiply by 10.0; potassium level to millimoles per liter, multiply by 1.0; serum creatinine to micromoles per liter, multiply by 88.4; and sodium to millimoles per liter, multiply by 1.0.

Variables relevant to the choice of MRA were selected for logistic regression model for developing a propensity score for the choice of MRA.

Risk-adjusting variables were selected for Cox proportional hazard models in the unmatched cohort.

To focus the association of LVEF, we performed post hoc analyses. First, we stratified the entire cohort into the 2 strata by LVEF (\<40% or ≥40%) and calculated the propensity score for the choice of MRA use in each LVEF stratum. Then, we generated the propensity score--matched cohort in the same fashion as the main analysis and compared the differences between the 2 groups in each LVEF stratum.

All statistical analyses were conducted by 2 of our physicians (H.Y. and Y.Y.) and our statistician (T. Morimoto) using JMP, version 13.0, and SAS, version 9.4 (SAS Institute Inc) or R (R Project for Statistical Computing). Two-tailed *P* \< .05 was considered statistically significant.

Results {#H1-3-ZOI190240}
=======

Patient Characteristics {#H2-4-ZOI190240}
-----------------------

In the study population of 3717 patients, 1678 (45.1%) patients had received MRA treatment at discharge and 2039 (54.9%) did not. The MRA treatment included spironolactone (median dose, 25 mg) in 1570 patients (93.6%) and eplerenone (median dose, 50 mg) in 108 patients (6.4%). Regarding the baseline clinical characteristics before matching, the patients in the MRA use group were younger and had a lower prevalence of previous heart failure hospitalization, hypertension, diabetes, dyslipidemia, previous percutaneous coronary intervention or coronary artery bypass graft, renal dysfunction, and anemia ([Table 1](#zoi190240t1){ref-type="table"}). No significant differences in body mass index, atrial fibrillation (AF) or atrial flutter (AFL), previous myocardial infarction, previous stroke, chronic lung disease, malignant neoplasm, and dementia were observed between the 2 groups ([Table 1](#zoi190240t1){ref-type="table"}). The MRA use group was more likely to have a hypertensive origin and AF or AFL at presentation, higher heart rate, lower blood pressure, lower levels of blood urea nitrogen and potassium, and a reduced LVEF ([Table 1](#zoi190240t1){ref-type="table"}). Regarding medical treatment at discharge, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, and loop diuretics were more often prescribed in the MRA use group ([Table 1](#zoi190240t1){ref-type="table"}).

The propensity score matching yielded a total of 2068 patients: 1034 patients in the MRA use group were matched to 1034 reference patients in the no MRA use group (main cohort: median \[IQR\] age, 80 \[72-86\] years; 937 \[45.3%\] women; mean \[SD\] LVEF, 46.7% \[16.0%\]). In the matched cohort, baseline characteristics were well balanced between the 2 groups, except for the slightly but statistically significantly better renal function in the MRA use group than in the no MRA use group ([Table 1](#zoi190240t1){ref-type="table"}).

Clinical Outcomes in the Matched and Entire Cohort {#H2-5-ZOI190240}
--------------------------------------------------

The median (interquartile range \[IQR\]) length of follow-up was 470 days (357-649 days), with a 96% follow-up rate at 1 year. In the propensity score--matched cohort, the cumulative 1-year incidence of the primary outcome measure (a composite of all-cause death or heart failure hospitalization) in the MRA use group was statistically significantly lower compared with the no MRA use group (28.4% vs 33.9%; HR, 0.81; 95% CI, 0.70-0.93; *P* = .003) ([Figure 2](#zoi190240f2){ref-type="fig"}A). The cumulative 1-year incidence of all-cause death was not statistically significantly different between the 2 groups (15.6% vs 15.8%; HR, 0.98; 95% CI, 0.82-1.18; *P* = .85) ([Figure 2](#zoi190240f2){ref-type="fig"}B and [Table 2](#zoi190240t2){ref-type="table"}), whereas the cumulative 1-year incidence of heart failure hospitalization in the MRA use group was statistically significantly lower than that in the no MRA use group (18.7% vs 24.8%; HR, 0.70; 95% CI, 0.60-0.86; *P* \< .001) ([Figure 2](#zoi190240f2){ref-type="fig"}C and [Table 2](#zoi190240t2){ref-type="table"}). The result was consistent with the result derived from the cumulative incidence function curves accounting for the competing risk of death by Gray test (eFigure 1 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}).

![Cumulative Incidence Rates of the Primary Outcome Measure in the Propensity Score--Matched Cohort\
Log-rank *P* = .003 (A), *P* = .85 (B), and *P* \< .001 (C). MRA indicates mineralocorticoid receptor antagonist.](jamanetwopen-2-e195892-g002){#zoi190240f2}

###### Clinical Outcomes in the Matched and Entire Cohort

  Outcome                                              Propensity Score--Matched Cohort   Entire Cohort                                                                                                        
  ---------------------------------------------------- ---------------------------------- --------------- ------------------ -------- ------------ ------------ ------------------ -------- ------------------ --------
  Composite of all-cause death or HF hospitalization   287 (28.4)                         344 (33.9)      0.81 (0.70-0.93)   .003     503 (30.6)   739 (36.8)   0.79 (0.71-0.88)   \<.001   0.81 (0.71-0.92)   .001
  HF hospitalization                                   179 (18.7)                         239 (24.8)      0.70 (0.60-0.86)   \<.001   335 (21.5)   494 (26.2)   0.77 (0.68-0.88)   \<.001   0.74 (0.63-0.87)   \<.001
  All-cause death                                      157 (15.6)                         159 (15.8)      0.98 (0.82-1.18)   .85      257 (15.7)   367 (18.4)   0.83 (0.72-0.95)   .007     0.93 (0.78-1.11)   .42
  Cardiovascular death                                 96 (9.8)                           93 (9.4)        1.07 (0.84-1.36)   .59      155 (9.8)    217 (11.3)   0.88 (0.74-1.05)   .16      1.03 (0.82-1.29)   .80
  Sudden death                                         23 (2.5)                           18 (1.9)        1.59 (0.93-2.78)   .09      33 (2.2)     43 (2.3)     1.09 (0.73-1.61)   .68      1.51 (0.92-2.45)   .10
  Any hospitalization                                  344 (35.3)                         375 (38.2)      0.88 (0.77-1.01)   .07      580 (36.6)   779 (40.8)   0.85 (0.77-0.94)   .002     0.84 (0.74-0.96)   .007

Abbreviations: HF, heart failure; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist.

Number of patients with at least 1 event reported as cumulative 1-year incidence, counted through the entire follow-up period.

Adjusted for the clinically relevant variables described in [Table 1](#zoi190240t1){ref-type="table"}.

In the subgroup analysis ([Figure 3](#zoi190240f3){ref-type="fig"}), no statistically significant interaction was observed between the HRs for the primary outcome measure associated with the use of MRA and the clinically relevant subgroup factors such as LVEF, age, sex, previous heart failure hospitalization, diabetes, myocardial infarction, AF or AFL, New York Heart Association class, estimated glomerular filtration rate, and use of the antagonists of the renin-angiotensin system and β-blocker (eTable 2 and eTable 3 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). Nevertheless, the association of MRA use with the primary outcome measure was greater in patients with HFpEF (25.9% vs 33.4%; HR, 0.75; 95% CI, 0.62-0.89; *P* = .001) than in those with HFrEF (33.1% vs 34.7%; HR, 0.93; 95% CI, 0.74-1.18; *P* = .56) ([Figure 3](#zoi190240f3){ref-type="fig"}; eFigure 2 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}).

![Subgroup Analysis for the Primary Outcome Measure in the Propensity Score--Matched Cohort\
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; and NYHA, New York Heart Association.](jamanetwopen-2-e195892-g003){#zoi190240f3}

In the entire cohort, the cumulative 1-year incidence of the primary outcome measure in the MRA use group was statistically significantly lower than that in the no MRA use group (30.6% vs 36.8%; *P* \< .001) (eFigure 3 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). After adjusting for baseline characteristics, the favorable association of the MRA use group compared with the no MRA use group remained statistically significant (adjusted HR, 0.81; 95% CI, 0.71-0.92; *P* = .001) ([Table 2](#zoi190240t2){ref-type="table"}). The results in the entire cohort for the secondary outcome measures, including all-cause death and heart failure hospitalization, were consistent with those in the propensity score--matched cohort ([Table 2](#zoi190240t2){ref-type="table"}; eFigure 3 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). No difference in any unexpected hospitalization was observed between the 2 groups in the propensity score--matched cohort (35.3% vs 38.2%; HR, 0.88; 95% CI, 0.77-1.01; *P* = .07), although the cumulative 1-year incidence of any unexpected hospitalization in the MRA use group was statistically significantly lower than that in the no MRA use group in the entire cohort (36.6% vs 40.8%; adjusted HR, 0.84; 95% CI, 0.74-0.96; *P* = .007) ([Table 2](#zoi190240t2){ref-type="table"}). The results in the entire cohort for the subgroup analysis stratified by LVEF (eFigure 4 and eTable 4 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}) were consistent with those in the propensity score--matched cohort.

Post Hoc Analyses {#H2-6-ZOI190240}
-----------------

Of the population of 3717 patients, 1383 (37.2%) showed reduced LVEF, and 2334 (62.8%) showed preserved LVEF (eFigure 5 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). Propensity score matching resulted in a total of 385 patients with HFrEF and 690 patients with HFpEF for the MRA use group or no MRA use group (eFigure 5, eTable 5, and eTable 6 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). In the matched cohort of patients with HFrEF, the cumulative 1-year incidence of the primary outcome measure was not statistically significantly different between the 2 groups (34.7% vs 33.7%; HR, 0.87; 95% CI, 0.78-1.21; *P* = .78) (eFigure 6 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). In the matched cohort of patients with HFpEF, the cumulative 1-year incidence of the primary outcome measure in the MRA use group was statistically significantly lower than that in the no MRA use group (26.8% vs 33.7%; HR, 0.78; 95% CI, 0.66-0.93; *P* = .005) (eFigure 6 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}). The results were consistent with the main results (eFigure 2 in the [Supplement](#note-ZOI190240-1-s){ref-type="supplementary-material"}) in the propensity score--matched cohort, including patients with HFrEF or HFpEF.

Discussion {#H1-4-ZOI190240}
==========

The main findings of the present study were as follows. First, the use of MRA at hospital discharge was associated with a lower risk for the primary outcome measure (a composite of all-cause death or heart failure hospitalization) in patients hospitalized for ADHF; however, MRA use did not seem to be associated with lower mortality but was associated with heart failure hospitalization. Second, when patients were stratified by LVEF at first, some advantages appeared to have potentially accrued to patients with HFpEF.

The clinical utility of MRA in stable patients with heart failure and reduced LVEF was first demonstrated in the Randomized Aldactone Evaluation Study (RALES) in 1991.^[@zoi190240r1]^ Subsequently, a line of evidence emerged that MRA treatment (spironolactone or eplerenone) was associated with reduced morbidity and mortality in patients with HFrEF.^[@zoi190240r2],[@zoi190240r14]^ The Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial^[@zoi190240r15]^ in patients with stable HFpEF suggested the reduction of heart failure hospitalization with MRA treatment, although the study failed to show the evidence for the mortality advantage of MRA treatment during the median follow-up of 3.3 years. However, to our knowledge, no previous RCT investigated the association of MRA use in patients hospitalized for ADHF with the postdischarge outcomes. Acute decompensated heart failure has the potential risk for decline and eventually in-hospital death. Even during the recovery phase, a certain proportion of patients hospitalized for ADHF are hemodynamically unstable, often with worsening renal function. Therefore, the optimal management of patients hospitalized for ADHF would be defined specifically in this patient population. In the case of β-blocker treatment, the heart failure guidelines recommend its early induction in patients with ADHF and reduced LVEF, although the recommendation was based on small studies showing the association between withdrawal of β-blocker therapy at admission for ADHF and an increase in mortality.^[@zoi190240r16],[@zoi190240r17],[@zoi190240r18],[@zoi190240r19]^

In the present study, MRA treatment was not associated with a lower risk for all-cause death but instead with heart failure hospitalization only in contemporary patients with ADHF who were discharged alive. To our knowledge, the baseline patient characteristics were substantially different from those in previous RCTs. A large proportion of patients with advanced age (median age of 80 years) and a substantial proportion of patients with comorbidities, such as chronic kidney disease and AF or AFL, were represented in this study. Despite these demographic differences, the favorable association of MRA with heart failure hospitalization but not with mortality in patients with HFpEF was consistent with findings reported in previous RCTs.

The mechanisms by which MRA may become potentially advantageous to patients with HFpEF from the point of heart failure readmission rate are uncertain. However, the neurohormonal pathways were excessively activated in a large proportion of patients with ADHF through sympathetic nerve systems, worsening renal function, and the aggressive use of loop diuretics.^[@zoi190240r20],[@zoi190240r21],[@zoi190240r22]^ The use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker was less common in HFpEF than in HFrEF. Therefore, the blockade of the renin-angiotensin system by MRA might have promoted the favorable association with heart failure hospitalization in patients with HFpEF. Another possible mechanism was the diuretic nature of MRA. In this study, the combination of MRA and loop diuretics was more frequently observed in patients with HFpEF. Long-term use of loop diuretics is associated with diuretic resistance through tubule-glomerular feedback mechanisms enhanced by renin-angiotensin-aldosterone system activation.^[@zoi190240r20],[@zoi190240r21],[@zoi190240r22]^ The blockade of aldosterone statistically significantly enhances the blockade of sodium reabsorption in the distal tubules and collecting duct. These speculated mechanisms were consistent with the observed favorable associations of MRA use with the heart failure readmission in patients with HFpEF.

However, no difference in all-cause mortality or any unexpected hospitalization was observed regardless of MRA use. One reason for this finding might be that many patients, particularly those with HFpEF, had many comorbidities owing to their advanced age. Thus, the outcomes of MRA may be counterbalanced by electrolyte imbalance, worsening renal function, and noncardiovascular mortality or hospitalization in patients who received MRA. Another consideration is that patients treated with MRA in the entire population were hypotensive, more likely to have reduced LVEF, and less likely to have ADHF from hypertensive heart disease. Therefore, the adverse effects of MRA use may have been avoided because the heart failure stage in the MRA use group was more progressive than the no MRA use group, although we performed the propensity score matching using 16 variables.

The lack of mortality advantage from MRA use despite a reduction in heart failure hospitalization was consistent with findings of an observational study in patients with ADHF and the TOPCAT trial.^[@zoi190240r3],[@zoi190240r5],[@zoi190240r15]^ The therapy to reduce heart failure hospital readmissions has an important role in daily practice in a rapidly aging society because repeated heart failure hospitalizations are associated with high mortality rates, diminished quality of life and functional status, inadequate recovery after heart failure deterioration, and the escalation of the medical costs.^[@zoi190240r23]^ In contrast, the rate of any unexpected hospitalization did not differ between the MRA use group and no MRA use group in the propensity score--matched cohort. Considering no differences in mortality or overall rate of hospitalization, MRA use may be associated with minimal, if any, clinical net advantages. Our additional analyses suggested the potential value of MRA use for patients with HFpEF. Exploratory studies to identify the patient groups that find MRA use advantageous are needed and should be confirmed by RCTs in patients hospitalized for ADHF.

Limitations {#H2-7-ZOI190240}
-----------

This study has several limitations. First, the observational study design is subject to selection bias and residual confounding. The KCHF registry had comprehensive data on patient demographics, medical history, underlying heart disease, prehospital activities, socioeconomic status, signs, symptoms, medications, laboratory tests, electrocardiogram, and echocardiography results, acute management in the emergency department, status at discharge, and clinical events during the index hospitalization. By adjusting for 25 variables, we accounted for most conceivable confounders. Nevertheless, residual unmeasured confounding could affect the results. Second, we had no prescription data after discharge from the index hospitalization; therefore, we could not deny the possibility of substantial crossover in MRA use. Third, this observational study used propensity score matching. Thus, we did not perform a confidence set or power analysis in advance. Further studies, including those on quality of life and cost, may clarify the clinical net advantage of MRA use in this cohort. Fourth, data on the reasons for MRA use or no MRA use by individual patients were not available.

Conclusions {#H1-5-ZOI190240}
===========

Use of MRA at discharge from ADHF hospitalization appeared to be associated with a lower risk of heart failure hospitalization but not with lower all-cause mortality or overall rate of hospitalization. These findings suggest that MRA use might be associated with minimal, if any, clinical advantage. Further studies appear to be needed to identify the patient groups that may find value in MRA treatment and for findings to be confirmed by RCTs in patients hospitalized for ADHF.
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